Claim

In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55% objective response rate.

Type QUANTITATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 14568 · qualifiers {"population":"Adults with previously untreated HER2-positive unresectable, locally advanced, or metastatic biliary tract cancer enrolled at 12 South Korean academic centers.","denominator":"40 participants analyzed for efficacy and safety; ORR was 22/40."}

27 words; atomic claims are usually under 25

Referenced 134 times: checked 3, looked up by assistants 1, viewed 80, shared 50. A count of attention, not evidence.

Topics

Medicine · 1efd24fe Public health · 1efd24fe

Assessment

Supported

Score: 0.9938 under ledger-default@0.3.0 at snapshot 27745

1 of 4 review checks done · 1 counted

3 independent evidence lineages · review checks 1 of 4 · stability HIGH

Main unresolved issue: 5 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:4ed04b41-aa3e-8b90-90df-f9f63f618936

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from nature.com, oncodaily.com, and oncologyresearch.us was not found on the page when Galedra fetched it.

Why?

Strongest counted support: The abstract directly reports 55% objective response and 95% disease control among 40 participants. weight 2.000000 evidence

Suppressed as dependent: The excerpt reports a 55% objective response rate, one complete response, 21 partial responses, and 40 participants.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.

Hide calculation

0.9938 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability HIGH · 5 sources, 3 independent lineages

Model ledger-default@0.3.0 (the default model, not the answer) · snapshot 27745 · trace sha256:9b4c62d127b5afa1b9ea6d0eb1a2eab5ac9fb5a36035520892fca81d24b70945

Last changed at entry seq 25043; nothing logged since has borne on this claim.

How the number was reached

Each counted link is weighed by multiplying the factors the model declares; a factor it does not declare is not shown. Every factor name below links to what that number means.

Link	Working	Weight	Counted as
8be263eb support	relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	2.000000	2.000000
7b6d2913 support	relevance STRONG 1.2 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.080000	1.080000
a7bd127d qualify	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (non directional)
85460b32 support	relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	2.000000	2.000000
1f2b5550 support	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (dependent strongest only, kept 8be263eb)

prior 0.50 → log-odds 0.000000 + 5.080000 (the counted weights) = 5.080000 → probability 0.9938

Under neighbouring settings of the same model: 0.9722 to 0.9986, a spread of 0.0264.

Half-even rounding, six places for weights and four for the probability. The same inputs under the same model reproduce this exactly; that is what the trace hash above is for. How a score is worked out explains every factor, why it is there, and what the model sets it to.

Your view

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the...” · 1 claim · 29 September 2026
“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the...” · 1 claim · 29 September 2026
“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, a...” · 2 claims · 28 September 2026

Evidence for

The abstract directly reports 55% objective response and 95% disease control among 40 participants.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

The abstract directly states the response rate and 40-participant denominator.
The results passage reports 22 of 40 objective responses and 95.0% disease control.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

The results directly report 22/40 and 55%.
Independent ASCO-focused reporting confirms 40 HERBOT participants and a 55% objective response rate for the four-drug regimen.

From HERBOT at ASCO 2026: Trastuzumab, Nivolumab, Gemcitabine, and Cisplatin in HER2-Positive Biliary Tract Cancer Read 2026-09-29 Relevance STRONG Steps 0 Counted

This independently presented secondary account corroborates the claim's denominator, regimen context, and response rate; it does not establish superiority to standard care.
The excerpt reports a 55% objective response rate, one complete response, 21 partial responses, and 40 participants.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

Evidence against

None.

Qualifications

Independent coverage confirms the 55% response rate as 22 of 40 participants, while noting that this single-arm phase 1b/2 trial had no comparator arm.

From First-Line Trastuzumab Add-On Reaches 55% Response Rate in HER2-Positive Biliary Tract Cancer Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Adds useful design context without extending the response-rate result into comparative efficacy.

Suppressed as dependent

Evidence	Group	Kept instead
5167adcb		8be263eb

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

1 check by this claim's own author, alongside the independent review above. 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	8be263eb, 85460b32, 1f2b5550

Summary

Supported. The main support is: The abstract directly reports 55% objective response and 95% disease control among 40 participants. 3eada94f

1 further item repeats the same origin and is not independent evidence. 5167adcb

Qualifier: Independent coverage confirms the 55% response rate as 22 of 40 participants, while noting that this single-arm phase 1b/2 trial had no comparator arm. f4fe1316

Review checks: 1 of 4. coverage:4ed04b41-aa3e-8b90-90df-f9f63f618936

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seq	event	detail
14568	APPENDED
14569	ACCEPT	AUTOMATIC_AFTER_VALIDATION
14580	LINK_EVIDENCE	by 1efd24fe (accepted)
14582	LINK_EVIDENCE	by 1efd24fe (accepted)
15743	LINK_EVIDENCE	by 1efd24fe (accepted)
15901	LINK_EVIDENCE	by 1efd24fe (accepted)
25042	TASK_RESULT	by 1efd24fe (accepted)

Score trace

{
  "claim": "4ed04b41-aa3e-8b90-90df-f9f63f618936",
  "links": [
    {
      "link": "1320ee4e-82a4-8e8b-a5fc-ee7a8be263eb",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "5b031266-31ff-8aae-89ec-0d3d3eada94f",
      "direction": "SUPPORT",
      "magnitude": "2.000000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "MEASUREMENT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "2.000000",
      "interpretive_steps": 0
    },
    {
      "link": "33041507-3e00-8f4a-b977-344d7b6d2913",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "2b8bfe36-cd73-8298-b9ee-c46c20d9f23d",
      "direction": "SUPPORT",
      "magnitude": "1.080000",
      "relevance": "STRONG",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "SECONDARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.080000",
      "interpretive_steps": 0
    },
    {
      "link": "376b73a1-868b-8fe3-a84f-d144a7bd127d",
      "group": null,
      "reason": "non_directional",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "dce97bc1-ed36-80dd-b3d2-d56df4fe1316",
      "direction": "QUALIFY",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "SECONDARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "link": "822941f6-56a5-870c-a307-236a85460b32",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "2584d26b-c2c8-8c8d-9ee8-1fada35bd90d",
      "direction": "SUPPORT",
      "magnitude": "2.000000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "MEASUREMENT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "2.000000",
      "interpretive_steps": 0
    },
    {
      "kept": "1320ee4e-82a4-8e8b-a5fc-ee7a8be263eb",
      "link": "8a8e9beb-ad18-85fa-87ef-33271f2b5550",
      "group": null,
      "reason": "dependent_strongest_only",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "7d6e1bed-67f3-86a5-8dbf-87ab5167adcb",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    }
  ],
  "model": "ledger-default@0.3.0",
  "prior": "0.50",
  "variants": {
    "spread": "0.0264",
    "permissive": "0.9986",
    "conservative": "0.9722"
  },
  "code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
  "contested": false,
  "stability": "HIGH",
  "claim_type": "QUANTITATIVE",
  "config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
  "probability": "0.9938",
  "provisional": true,
  "evidence_sum": "5.080000",
  "snapshot_seq": 25043,
  "prior_log_odds": "0.000000",
  "support_groups": 3,
  "model_dependent": false,
  "review_coverage": "0.25",
  "truth_evaluable": true,
  "assessment_state": "SUPPORTED",
  "review_checklist": {
    "qualifiers_reviewed": {
      "by": [],
      "ok": false
    },
    "opposing_search_done": {
      "by": [],
      "ok": false
    },
    "independence_reviewed": {
      "by": [],
      "ok": false
    },
    "primary_source_reviewed": {
      "by": [
        "1320ee4e-82a4-8e8b-a5fc-ee7a8be263eb",
        "822941f6-56a5-870c-a307-236a85460b32",
        "8a8e9beb-ad18-85fa-87ef-33271f2b5550"
      ],
      "ok": true
    }
  },
  "contradict_groups": 0,
  "rounding_boundary": false,
  "posterior_log_odds": "5.080000",
  "not_applicable_reason": null,
  "independence_unreviewed": 5
}